Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.49 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6161042 | 1.00 | GRIK1 (0.49) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL7304504 | 0.98 | GRIK1 (0.50) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL6138155 | 0.98 | GRIK1 (0.50) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL7066300 | 0.98 | GRIK1 (0.50) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL7075183 | 0.98 | GRIK1 (0.50) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL7069281 | 0.98 | GRIK1 (0.50) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL8217023 | 0.98 | GRIK1 (0.50) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL8217020 | 0.98 | GRIK1 (0.50) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL6808467 | 0.98 | GRIK1 (0.50) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL27573982 | 0.98 | GRIK1 (0.50) | GRIK1GRIK2SLC1A2SLC1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-29 | — | — | US | claimed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | claimed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | claimed |
| US-20050272667-A1 | Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor | SCHEINBERG DAVID | 2005-12-08 | — | — | US | disclosed |
| EP-1372692-A4 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INST CANCER (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6887887-B2 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-29 | — | — | US | disclosed |
| EP-1372692-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | Sloan Kettering Institute For Cancer Research (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | disclosed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | disclosed |
| WO-2002074050-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-09-26 | — | — | WO | disclosed |
| EP-0621270-B1 | Piperazine derivatives as collagenase inhibitors | SANKYO CO (JP) | 2000-04-12 | — | — | EP | disclosed |
| US-5643908-A | ANGIOGENESIS INHIBITOR, ANTITUMOR | SANKYO COMPANY, LIMITED (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0621270-A1 | COLLAGENASE INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1994-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, ACTR3 | GRIK1 4803/4885GRIK2 4693/4885SLC1A2 2195/4885 |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, CYTH3 | GRIK1 4814/4885GRIK2 4703/4885SLC1A2 2191/4885 |
| US-20050272667-A1 | Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor | CYTH3, ACTR3, HASPIN | GRIK1 4809/4885GRIK2 4768/4885SLC1A2 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.